This inventor holds 1 USPTO granted patent. Top assignee: State of Oregon. Active years: 1992.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992
Title: John F Witte: Innovator in Drug Targeting Technologies
Introduction
John F Witte is a notable inventor based in Portland, OR (US). He has made significant contributions to the field of drug targeting through his innovative approaches. His work focuses on enhancing the efficacy of drug delivery systems, particularly in the treatment of diseases.
Latest Patents
Witte holds a patent for "Covalent lipid-drug conjugates for drug targeting." This invention relates to a novel method of drug targeting that involves covalently binding a drug to a lipid carrier. The composition has the unique ability to enhance the rate at which an antineoplastic or antiviral drug crosses the plasma membrane. Additionally, it directs the drug within the cell to specific organelles. The versatility of these conjugates is further enhanced by including a spacer group between the drug and the lipid, which may modulate drug release at the target site. He has 1 patent to his name.
Career Highlights
Witte's career has been marked by his dedication to advancing drug delivery technologies. His innovative methods have the potential to significantly improve treatment outcomes for patients. He works in the State of Oregon, contributing to the local research and development landscape.
Collaborations
Throughout his career, Witte has collaborated with esteemed colleagues, including Milton Yatvin and David W Parks. These collaborations have fostered a rich environment for innovation and have led to the development of groundbreaking technologies in drug targeting.
Conclusion
John F Witte's contributions to drug targeting technologies exemplify the impact of innovation in the medical field. His work continues to pave the way for advancements that can enhance patient care and treatment efficacy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
